PDF

Theranostics 2020; 10(20):8924-8938. doi:10.7150/thno.47118 This issue Cite

Review

An emerging role of regulatory T-cells in cardiovascular repair and regeneration

Tiffany H.W. Fung¹, Kevin Y. Yang^1,2, Kathy O. Lui^1,2,3

1. Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
2. Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
3. Li Ka Shing Institute of Health Sciences, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.

✉ Corresponding author: E-mail: kathyoluiedu.hk (K.O.L.).

Abstract

Accumulating evidence has demonstrated that immune cells play an important role in the regulation of tissue repair and regeneration. After injury, danger signals released by the damaged tissue trigger the initial pro-inflammatory phase essential for removing pathogens or cellular debris that is later replaced by the anti-inflammatory phase responsible for tissue healing. On the other hand, impaired immune regulation can lead to excessive scarring and fibrosis that could be detrimental for the restoration of organ function. Regulatory T-cells (Treg) have been revealed as the master regulator of the immune system that have both the immune and regenerative functions. In this review, we will summarize their immune role in the induction and maintenance of self-tolerance; as well as their regenerative role in directing tissue specific response for repair and regeneration. The latter is clearly demonstrated when Treg enhance the differentiation of stem or progenitor cells such as satellite cells to replace the damaged skeletal muscle, as well as the proliferation of parenchymal cells including neonatal cardiomyocytes for functional regeneration. Moreover, we will also discuss the reparative and regenerative role of Treg with a particular focus on blood vessels and cardiac tissues. Last but not least, we will describe the ongoing clinical trials with Treg in the treatment of autoimmune diseases that could give clinically relevant insights into the development of Treg therapy targeting tissue repair and regeneration.

Introduction

As the healthcare of the population improves, the life expectancy of people has been increasing. However, a significant proportion of the population is crippled by chronic non-communicable diseases, placing huge burdens on the societies of the developed countries. These chronic conditions, including the most common co-morbidities: type 2 diabetes, Alzheimer's disease, hypertension, coronary artery disease, and heart failure; are associated with the dysregulation of immune system leading to chronic inflammation [1-5]. Currently the therapeutic approach focuses on the prevention of progression and deterioration for these diseases, but there is no complete cure. Therefore, extensive research has been performed in the search for alternative treatment options.

The immune system has been a particular field of interest, as it can regulate not only the physiological processes of inflammation, but also tissue repair and regeneration. However, excessive anti-inflammatory response in the resolution process could lead to pathological fibrosis. Therefore, a tight regulation of the anti-inflammatory response dictates the outcome whether the inflamed tissue is replaced by scar tissue, or replaced with the regenerated tissue to restore organ function after injury [6]. The study of the immune cell mediators essential to the repair and regeneration of injured tissue is attractive to search for new therapeutic targets, although the mechanisms by which the immune cells coordinate to mediate organ repair and regeneration have been less studied.

Regulatory T-cells (Treg) are well-known for their immunomodulatory properties to resolve inflammation or prevent the inappropriate activation of inflammation leading to autoimmunity. Apart from this, there is an emerging evidence that they participate in local tissue regeneration, and by manipulating such property of Treg to tip the balance from fibrotic resolution that usually occurs in adults, to a pro-regenerative one with restoration of organ function. This review is a compilation of the overall picture of the spectrum of Treg function regarding their immunomodulatory and reparative functions, with specific focus on the most recent findings on the role of Treg in angiogenesis and cardiomyocyte regeneration.

The Immune Role of Treg in Tolerance

Treg are considered as key mediators for the establishment of peripheral tolerance, as their immunosuppressive function dampens or prevents the immune system to mount an inflammatory response inappropriately towards self-antigens, commensal microbiota, food and environmental antigens, which would otherwise lead to the deleterious effects of autoimmunity and allergy, respectively [7, 8]. Treg have also been shown to play a pivotal role in preventing the rejection of murine and human stem cell transplants [9, 10]. The development of Treg from the thymus and periphery has been reviewed extensively [11, 12]. Several mechanisms have been proposed to be deployed by Treg to exert their immunosuppressive function on the effector cells of both the innate and adaptive arms of immunity, including macrophages, neutrophils, NK cells, dendritic cells, and T cells particularly CD4⁺ and CD8⁺ T cells. The mechanisms of action include direct cell-cell interaction, paracrine signalling, metabolic disruption and induction of apoptosis (Figure 1).

The molecules expressed on the surface of Treg which have been identified to confer their suppressive functions include CTLA-4, LAG-3, and HVEM. For instance, Treg can suppress dendritic cells through CTLA-4, which binds with B7 molecules CD80 and CD86 on dendritic cells to induce the production of indoleamine 2,3-dioxygenase (IDO) by dendritic cells that suppresses the proliferation of effector T cells [13, 14]. LAG-3 expressed on Treg can also inhibit the maturation of dendritic cells through binding to their MHC-II [15]. Moreover, Treg can directly suppress CD4⁺ effector T cells through the binding of the inhibitory costimulatory molecules HVEM/BTLA [16], and CTLA4/B7 [17].

The release of cytokines IL-10, TGF-β, and IL-35 is crucial to the immunosuppressive functions of Treg, as shown in their regulation of allergic inflammation including asthma, and other autoimmune diseases [18-20]. These cytokines are able to directly suppress or pose the polarization of a pro- to anti-inflammatory phenotype of the immune cells including neutrophils, macrophages and effector T cells. For example, the ability of Treg to suppress the infiltration of neutrophils in the kidney after ischaemic-reperfusion injury is IL-10 dependent, as this phenomenon is abolished in cell specific knockout of IL-10 in Treg [21]. Treg can also target the pro-inflammatory M1 macrophages and the release of IL-10 is thought to contribute to the induction of their conversion to anti-inflammatory and pro-repair M2 macrophages [22]. Despite the controversy surrounding whether the expression of TGF-β is essential for Treg suppressive function, more recent evidence from transfer models of TGF-β1-deficient Treg shows that TGF-β1 produced by Treg is important in the prevention of colitis by suppressing the differentiation of Th1 cells [23] that are the mediators of the development of colitis [24]. IL-35 has also been identified to play an important role, as recombinant IL-35 alone was demonstrated to suppress the proliferation of CD4⁺ effector T cells in vitro [20].

Furthermore, Treg have been demonstrated to regulate immune cell mediators through metabolic disruption. Whether competitive consumption of IL-2 with effector T cells through the high affinity IL-2 receptors on Treg has been a controversial topic, but more recent evidence has shown that interruption of the IL-2 signalling pathway is an essential mechanism in suppressing the activation of CD8⁺ T cells, whereas IL-2 is dispensable for the control of CD4⁺ T cells [25]. Depletion of IL-2 has also been shown to suppress the activation of NK cells in vivo, suggesting that IL-2 is essential for the activation of both the innate and adaptive arms of immunity [26]. Another mechanism of suppression by Treg involves the production of adenosine. Treg express ectoenzymes CD39 and CD73 on the surface, which catalyse the degradation of nucleotides such as ATP into adenosine. The overall effect is an anti-inflammatory one, as adenosine can inhibit the proliferation and production of cytokines by activated CD4⁺ effector T cells through binding to A2A receptors, whereas the depletion of ATP, a pro-inflammatory signal, implies that there is reduced ATP-induced dendritic cell maturation, or ATP-induced release of pro-inflammatory cytokine IL-1β by monocytes [27-29].

 Figure 1 

Mechanisms of immune suppression by Treg. (A) Treg can suppress their target cells through direct cell-cell interaction. CTLA4/B7 interaction between Treg and dendritic cells can induce IDO production by dendritic cells, and the overall effect of reduction in tryptophan suppresses the proliferation of effector T cells. LAG3/MHCII interaction between Treg and dendritic cells suppresses dendritic cell maturation. CD4⁺ effector T cells are suppressed by the HVEM/BTLA and CTLA4/B7 interaction with Treg. (B) Treg also demonstrates paracrine signalling to suppress its targets. IL-10 is shown to suppress the infiltration of neutrophils in the kidney after ischaemic-reperfusion injury. IL-10 can also induce the conversion from M1 macrophages to M2 macrophages. TGF-β1 is also demonstrated to suppress the differentiation of Th1 cells and prevent the development of colitis. IL-35 can suppress the proliferation of CD4⁺ effector T cells. (C) Another mechanism is metabolic disruption. High affinity IL-2 receptors expressed by Treg depletes IL-2, and this suppresses the activation of CD8⁺ T cells, CD4⁺ T cells and NK cells. The ectoenzymes CD39 and CD73 expressed on Treg cell surface catalyse the conversion of ATP to adenosine. Increased adenosine levels inhibit the proliferation and cytokine release by activated CD4⁺ effector T cells. The overall effect of reduction of ATP leads to reduced maturation of dendritic cells and reduced release of pro-inflammatory IL-1β by monocytes. (D) Treg can induce apoptosis on immune mediators through granzyme/ perforin pathway, and they include monocytes, dendritic cells, NK cells, CD4⁺ and CD8⁺ T cells.

Last but not least, Treg demonstrate the ability to induce apoptosis of immune cell mediators, through the granzyme/ perforin pathway. Evidence has shown that Treg can release Granzyme B, and elicit apoptosis of target cells including monocytes, dendritic cells, NK cells, CD4⁺ and CD8⁺ T cells through a perforin-dependent pathway [30, 31]. Moreover, it is suggested that Treg can also exert the cytotoxic effects through the TRAIL/DR5 pathway, as the inhibition of this pathway abolishes the cytotoxic and suppressive effects of Treg on CD4⁺ T cells in vitro [32].

The Tissue Diversity of Treg

Previously, Treg are divided into two major groups according to their origin, namely thymus-derived (tTreg), and peripherally-derived (pTreg) Treg. The latter is a group of Treg formed by conversion of conventional CD4⁺ T cells in the periphery. However, this classification is not sufficient to represent the diversity and heterogeneity of Treg, as further characterisation of the phenotype and function of Treg shows that distinct subpopulations of Treg reside in non-lymphoid tissues, and display non-immune functions that are unique to the tissue type. Each tissue-resident Treg population is unique in terms of the expression of transcription factors, recruitment by chemokines and adhesion receptors, and effector functions [33].

Treg that reside in the adipose tissue are the best-characterised tissue-resident Treg so far. They comprise more than half of the CD4⁺ T cell population, compared to those found in lymphoid organs that contain less than 30% of the CD4⁺ T cell population [34]. At the gene expression level, compared to those residing in the lymphoid tissue, adipose tissue-resident Treg upregulate genes that are involved in leukocyte migration and extravasation (Gm1960, CCR1, CCR2, CCR9, CCL6, integrin alpha V, Alcam, CXCL2, CXCL10), and, in particular, the Il10 transcript is overexpressed by 136-fold compared to those of the lymphoid tissue [34]. PPAR-γ is also over-expressed in adipose tissue-resident Treg that is identified as the factor important for their accumulation, phenotype and function in adipose tissue [35]. The function of adipose tissue-resident Treg has been suggested to suppress the inflammation in adipose tissue and to maintain insulin sensitivity, as the depletion of adipose tissue-resident Treg to 30% of the usual levels shows increase in inflammatory mediators in visceral fat depot and insulin resistance [34].

Tissue-resident Treg are unique in their phenotype and function, as Treg that reside in other tissues such as the skin have distinctly different phenotype and function compared to that of the adipose tissue-resident Treg. Treg that reside in the skin are characterised by the expression of CCR4 and CD103 [36]. The role of skin-resident Treg is to suppress autoimmune and overactive inflammatory responses, as shown in experiments with the transfer of Fut7-deficient Treg to neonatal scurfy mice. Scurfy mice lack Treg, and Fut7 is an enzyme that produces E- and P-selectin, which are required for homing of Treg to the skin. Transfer of Fut7-deficient Treg to neonatal scurfy mice induced dermatitis, which is not seen after transfer of WT Treg [37]. Consistent with the results in mice, human patients with autoimmune skin conditions including systemic sclerosis and dermatomyositis show reduced Treg levels and reduced serum levels of TGF-β and IL-10 [38, 39].

Altogether, adipose tissue- and skin-resident Treg are examples illustrating the diversity in the phenotype and function of tissue-resident Treg. In fact, they have been identified in many non-lymphoid organs such as the lung, liver, pancreas, skeletal muscle, and intestine [40]. Whether these resident Treg represent a homogenous population of a particular tissue type remains elusive. Future studies should focus on the cellular, molecular and functional heterogeneity of resident Treg of each tissue type at a single cell resolution.

The Reparative Role of Tissue-Resident Treg

Tissue-resident Treg exhibit a diverse spectrum of functions, and in fact, Treg residing in some tissue types have displayed reparative functions, including induction of the regeneration of parenchymal cells in skeletal muscle, lung, gut and hair follicle of the skin (Figure 2). They promote tissue repair and regeneration through a direct interaction with the progenitor or stem cells; and/or an indirect effort to build a reparative niche to support the progenitor or stem cells.

Promoting repair through interacting with tissue progenitor cells

In the skeletal muscle, one aspect of Treg promoting repair and reducing damage from inflammation is through the conversion of macrophages from the pro-inflammatory M1 to anti-inflammatory and pro-repair M2 phenotype. As demonstrated in a model for Duchenne muscular dystrophy, the depletion of Treg resulted in an increased level of activated M1 macrophages, reduced M2 macrophages, and deterioration of muscle damage and inflammation, suggesting that Treg reduce damage and promote repair through regulating the ratio of M1:M2 macrophages [41]. The mechanism by which Treg regulate macrophage polarization in the context of tissue repair and regeneration has not been fully studied. One potential mechanism is through suppression of IFNγ produced by CD4⁺ effector T cells, and IFNγ is a promoter of formation of M1 macrophages, but whether there are other direct mechanisms, perhaps related to the increased in IL-10 level in muscle, has not yet been explored or investigated [41]. The polarisation of macrophages from a M1 to M2 phenotype is important in muscle repair, as immediately after injury, M1 macrophages take part in the phagocytosis of necrotic debris and induce proliferation of myogenic precursor cells, and the timely switch to M2 macrophages functions to induce the differentiation of myogenic precursor cells for myogenesis [42]. A more direct mechanism by which Treg promotes the regeneration of skeletal muscle is mediated through the release of amphiregulin (AREG) that has shown to stimulate the differentiation of satellite cells [43]. Satellite cells are activated after muscle injury, and are unipotent adult stem cells that are the source of regenerating muscle fibres [44]. Skeletal muscle resident Treg release AREG in vitro and in vivo, and at significantly higher levels compared to those of the lymphoid organs [43]. Treg ablation disrupts the myogenesis from satellite cells post-injury resulting in disorganised muscle fibres and muscle inflammation [43].

The release of AREG by tissue resident Treg is not exclusive to skeletal muscle, and is also demonstrated in the lung. Two mediators released by Treg are implicated in the repair of lung tissue after acute lung injury, including AREG and keratinocyte growth factor (KGF). The release of AREG by lung-resident Treg at as early as day 3 after influenza viral infection, and mice with AREG-deficient Treg display more severe lung tissue injury and deterioration of lung function, suggesting that AREG is important in the repair of lung tissue post-injury and restoration of lung function, although the mechanism underlying how AREG repairs the lung tissue remains elusive [45]. Apart from AREG, there is also evidence that lung-resident Treg release KGF after acute lung injury, and KGF is able to induce the proliferation of alveolar epithelium as evidenced by the fact that mice with KGF-deficient Treg have significantly reduced proliferation of alveolar epithelial cells and among these AT2 cells (type 2 alveolar epithelial cell) in particular in vivo, and co-culture of KGF-deficient Treg with AT2 cells in vitro reduced their proliferation rate [46].

In addition to growth factors, cytokines such as IL-10 released by gut-resident Treg are also important in the maintenance of the stem cell pool by promoting their self-renewal in the intestine, as Treg ablation resulted in an altered differentiation of the intestinal epithelial cells, due to the decreased pool of intestinal stem cells, and the increased accumulation of Th1, Th2, and Th17 cells, where these cells suppress the renewal of intestinal stem cells, and cytokines released by Th1 and Th2 cells can also modulate lineage commitment of these intestinal stem cells, although it has not been shown whether the Treg play a role in regulating the ratio of Th1 and Th2 cells to control the proportion of the differentiated cells [47].

Apart from the release of growth factors by Treg to induce repair, they can also induce the reparative process through contact-dependent mechanisms to activate the progenitor cells directly. In hair follicles, skin-resident Treg mainly reside in the hair follicles [48], and due to the close proximity to the hair follicle stem cells, they can induce regenerative process by the expression of Jag1, which activates the Notch signalling pathway of hair follicle stem cells directly, resulting in their proliferation and differentiation [49].

Promoting repair through creating an appropriate stem cell niche

In addition to directly working with the stem or progenitor cells, Treg also facilitate repair of local tissue through interacting with the supportive cells of the microenvironment that support stem or progenitor cells in the skin, neural tissue, and bone marrow. In the repair of the epidermal layer of the skin after injury, the migration of hair follicle stem cells to the upper epidermis and their differentiation into keratinised epithelial cells as an alternative fate is required for restoring the skin barrier, and Treg are essential regulators of this process [50]. It is thought that one mechanism is mediated by the suppression of the CXCL5/Th17/neutrophil axis, including the inhibition of the release of IL-17A by Th17 cells, the release of CXCL5 by keratinocyte, and neutrophil recruitment as CXCL5 is a neutrophil chemoattractant [50].

Furthermore, Treg have been shown to promote oligodendrocyte differentiation, which is an essential process during the remyelination of neurones of the central nervous system [51]. It is hypothesised that this process is mediated by the production of CCN3 by Treg from in vitro studies [51]. Treg can also maintain the function of bone marrow stromal cells, in particular, and regulate the release of IL-7 from ICAM1⁺ perivascular stromal cells which is important in supporting the development of lymphoid lineage, including the differentiation of B cells from haematopoietic stem cells [52].

 Figure 2 

Reparative role of tissue-resident Treg. (A) Treg can promote repair through direct interaction with tissue progenitor cells. Skeletal muscle-resident Treg promotes the conversion of M1 to M2 macrophages, and the timely switch is important in muscle repair, as M1 macrophages are responsible for inducing proliferation of myogenic precursor cells, whereas M2 macrophages promote the differentiation of myogenic precursor cells. Skeletal muscle-resident Treg also releases AREG which stimulates the differentiation of satellite cells. Lung-resident Treg releases AREG and KGF, and AREG is important lung tissue repair post-influenza infection, whereas KGF induces the proliferation of AT2 cells in the alveolar epithelium. Gut-resident Treg releases IL-10 promotes the self-renewal of stem cells in the intestinal epithelium. Skin-resident Treg in hair follicles can induce the proliferation and differentiation of hair follicle stem cells through Jag1/Notch interaction. (B) Treg interact with supportive cells to create an appropriate stem cell niche for tissue repair. Skin-resident Treg inhibit the CXCL5/Th17/neutrophil axis, which includes Th17 releasing IL-17A, IL-17A inducing the release of CXCL5 by keratinocyte, and CXCL5 recruiting neutrophils. The overall effect of the inhibition of the axis is the migration of hair follicle stem cells to the upper epidermis and their differentiation into keratinised epithelial cells for repair of the skin barrier (Adapted with permission from [50], copyright 2019 Elsevier Inc.). Nerve-resident Treg releases CCN3, which is thought to promote oligodendrocyte differentiation, and thus the remyelination of neurones in the central nervous system. Bone marrow-resident Treg regulates the release of IL-7 from ICAM1⁺ perivascular stromal cells, which supports the development of lymphoid lineage including the differentiation of B cells from haematopoietic stem cells (Adapted with permission from [52], copyright 2017 Nature Research).

The mechanism underlying this requires further investigation, as it is unknown whether the bone marrow-resident Treg interact with the stromal cells directly, or through the suppression of activated CD4⁺ and CD8⁺ T cells, as increased levels of activated CD4⁺ and CD8⁺ T cells are detected in the bone marrow after Treg depletion [52]. Nevertheless, follow up study is lacking to determine whether activated CD4⁺ and CD8⁺ T cells alone can negatively regulate the IL-7 production by ICAM1⁺ perivascular stromal cells [52].

Treg in Cardiovascular Repair and Regeneration

Given that cardiovascular disease is the leading cause of deaths worldwide, novel insights into the development of potential therapeutics against cardiovascular diseases are needed. Recently, accumulating evidence supports the role of Treg in promoting angiogenesis, and facilitating the repair and regeneration of endothelial cells as well as cardiomyocytes. We will focus on the unappreciated role of Treg in the repair of blood vessels and heart muscle in this section.

Angiogenesis

The first evidence that Treg may play a role in angiogenesis is based from studies in tumours, where tumours exploit such mechanisms to fuel their proliferation. In murine ovarian cancer cell lines, recruited Treg are one of the main sources of VEGF_A in the tumour microenvironment, as the levels of VEGF_A and tumour microvascular density are significantly reduced after the administration of the anti-CD25 antibody that depletes Treg [53]. In addition, hypoxic conditions cause Treg to secrete significantly higher amount of VEGF_A, and the culture medium of hypoxic Treg is able to induce the expansion of CD31⁺ endothelial cells in vitro, leading to significantly greater capillary endothelial network, suggesting an important role for Treg in tumour angiogenesis [53].

The findings in hypoxic conditions are consistent with observations in the model of hindlimb ischemia that can recapitulate human peripheral arterial disease. After ligation of the femoral artery, Treg are likely key contributors for the reperfusion of the ischaemic limb, as administration of the anti-CD25 antibody profoundly reduces the extent of reperfusion achieved in the ischaemic limb compared to the control group [54]. Similarly, in another study, adoptive transfer of Treg improves the reperfusion of the ischaemic limb compared to the untreated controls; and immunohistochemistry on the ischemic tissues also shows that there are more CD31⁺SMA⁺ blood vessels, suggesting that Treg promote revascularisation of the ischaemic limb in vivo [55]. Mechanistically, IL-10 has been proposed to be the mediator by which Treg induce post ischemic angiogenesis, as IL-10 mRNA expression is reduced in the ischaemic limb after ablation of Treg by the anti-CD25 antibody; and the administration of IL-10 blocking antibody can completely abolish the beneficial effects from the adoptive transfer of Treg on post ischemic angiogenesis [55].

In addition to VEGF_A and IL-10, other Treg associated paracrine factors have been found effective in promoting angiogenesis even in hyperglycaemic conditions. For instance, co-culturing of murine endothelial cells with Treg or Treg culture medium shows increased tube formation, and although the components of the culture medium is not analysed, IL-10 and AREG are shown to be secreted by Treg in other context including in immunosuppressive mechanisms and in repair of skeletal muscle, and culturing the endothelial cells with IL-10 or AREG alone can reproduce the results of increased tube formation, and increase the expression of Apelin that is associated with sprouting angiogenesis, suggesting that these factors could be the underlying mediators [54]. Further investigation reveals that Treg or IL-10 can promote the proliferation of endothelial cells directly, which can account for the increased tube formation by endothelial cells, although AREG could act through a different mechanism other than inducing the endothelial cell proliferation to promote angiogenesis [54].

These findings support the ability of Treg to promote angiogenesis and proliferation of endothelial cells in specific conditions including hypoxia, ischaemia and hyperglycaemia (Figure 3). In addition to their paracrine effect, Treg could also mediate angiogenesis by inhibiting the activities of CD4⁺ Th1 cells [54] or CD8⁺ T cells [56]. In mice with normal blood glucose levels, Treg facilitate endothelial cell proliferation and regeneration by sprouting angiogenesis after ischemic injury [54]. However, such a regenerative ability of endothelial cells is lost in diabetic mice in which sprouting angiogenesis is negatively regulated by CD4⁺ Th cells [54] and CD8⁺ T cells [56], respectively. Blocking activation of these cells by their respective checkpoint inhibiting antibodies rescues vascular regeneration in diabetic mice, suggesting that Treg that inhibit their activation could also promote angiogenesis in a similar manner. Furthermore, Treg mediated response is often antigen specific. It has been demonstrated that induced angiogenesis by Treg is found only in the ischaemic but not the non-ischemic limb [54]. Moreover, the pro-angiogenic effects by Treg may be unique to the tissue type. For instance, lung tissue resident Treg are found to suppress angiogenesis by promoting the apoptosis of murine pulmonary endothelial cells through the DLL4-Notch signalling pathway [57]. Therefore, future studies should explore the self-antigen and tissue specificity of Treg in the regulation of angiogenesis, and elucidate a more complete profile of paracrine factors derived from them that might give insights into the development of therapeutics promoting tissue specific angiogenesis.

 Figure 3 

Treg in angiogenesis. Treg can promote angiogenesis under hypoxic or hyperglycaemic conditions. The main source of VEGFA for tumour angiogenesis in ovarian cancer cell lines is from recruited Treg, and VEGFA promotes the expansion of CD31⁺ endothelial cells. Treg also promotes angiogenesis in ischaemic hindlimb through the release of IL-10, although the mechanism remains unknown. IL-10 released by Treg also improves hindlimb ischaemia in hyperglycaemia, and both IL-10 and AREG can promote angiogenesis. IL-10 is demonstrated to promote the proliferation of CD31⁺ endothelial cells under hyperglycaemic conditions, although the mechanism for AREG in inducing angiogenesis remains unknown.

Cardiomyocyte repair and regeneration

In lower vertebrates such as the zebrafish, Treg have been demonstrated to promote adult heart regeneration [58]. In mammals, however, the adult heart is notorious in its inability to regenerate as proliferation of adult cardiomyocytes is negligible that cannot account for the recovery of large necrotic areas [59]. Unlike the adult heart, the mammalian neonatal heart is still capable of regenerating as cardiomyocytes can still proliferate during the first week of age [60] but the degree of regeneration is dependent on the size of injury [61]. Nevertheless, Treg have been demonstrated to facilitate adult heart repair and neonatal heart regeneration after myocardial injuries [62-64], possibly through different mechanisms of action (Figure 4). The ablation of Treg with diphtheria toxin results in left ventricular dilatation and reduced cardiac function in the adult FOXP3^DTR mice at 7 days after myocardial infarction (MI) [62]. Similarly, the administration of the lytic anti-CD25 antibody that depletes Treg increases lethal outcomes including apical aneurysm and cardiac rupture in the adult mice after MI compared to the untreated control group [63]. In addition, the depletion of Treg by the anti-CD25 antibody or ablation of Treg with diphtheria toxin in FOXP3^DTR mice results in an increased histological features of cardiac fibrosis and reduced proliferation of cardiomyocytes after injury in the neonatal stage [64]. Adoptive transfer of Treg, on the other hand, promotes neonatal heart regeneration by facilitating cardiomyocyte proliferation [64]; and improves cardiac function and suppresses adverse cardiac remodelling in the adult mouse heart after injury [65]. The administration of the superagonistic anti-CD28 antibody that shows to activate Treg can also lead to reduced cardiac rupture and improved survival [62]. Altogether, these reports suggest that Treg offer protection to prevent lethal complications and buffer the deterioration of cardiac function after myocardial injuries through reducing the adverse remodelling of the myocardium in the adult heart, and reducing fibrosis and increasing regeneration of cardiomyocytes in the neonatal heart.

 Figure 4 

Treg in cardiomyocyte regeneration. Treg is crucial in the repair of myocardium post-MI in both adult and neonatal mice. One mechanism proposed is the modulation of M2 macrophages, which promote the formation of scar tissue after MI. However, perhaps due to the different subtypes of M2 macrophages identified in neonatal and adult mice in the myocardium, Treg promotes the expression of M2 cytokines by M2 macrophages in adults but suppresses them in neonatal mice post-MI. Another mechanism of promoting myocardium repair is through the production of adenosine from CD39 expressed on Treg cell surface, and adenosine protects cardiomyocytes from apoptosis by activating RISK pathway. Treg can also directly influence the proliferation of cardiomyocytes in neonates and adults after MI. Even though adult cardiomyocytes do not possess inherent regeneration potential unlike neonatal cardiomyocytes, after MI, Treg promotes the proliferation of cardiomyocytes despite the mechanism remains unknown. Several paracrine factors released by Treg have been identified to promote neonatal cardiomyocytes proliferation, and they include CCL24, GAS7, AREG, CSR7, TNFSF11, IL33, FGL2, MATN2, and IGF2.

Mechanistically, it has been proposed that Treg facilitate the repair of heart tissue and cardiac function by immunomodulation of macrophages. An in vitro study shows that Treg promote the modulation of macrophages to a M2-like phenotype [62]. However, in the context of heart recovery, it remains unclear whether the cell fate of macrophages can be polarized in the cardiac tissue after injury; and whether the conversion to M2 macrophages is beneficial to the repair of the myocardium especially in the neonatal heart where fibrosis is less commonly seen than the adult counterpart. In the neonatal mice, an increased level of M2 macrophages is found in the non-regenerating heart when Treg are ablated, whereas a reduced level of M2 is observed in the regenerating heart after adoptive transfer of Treg [64]. In the adult mice, there are reduced expression levels of M2 and elevated levels of M1 cytokines in the scar tissue after the ablation of Treg [62]. One reason to explain the difference is that the populations of macrophages in the neonatal and adult myocardium could be distinct phenotypically and functionally given the difference in the developmental stages. For instance, 4 distinct populations can be detected in the adult mice distinguished by the expression levels of CCR2, MHCII, LYVE1 and TIMD4 [66]. The proportions and functions of different subpopulations of cardiac macrophages have altered after MI [67, 68]. Furthermore, neonatal heart repair heavily relies on resident macrophages that promote cardiomyocyte proliferation and coronary angiogenesis; whereas adult cardiomyocytes cannot proliferate so the recruited peripherally derived macrophages could operate differently [69]. Although M2 macrophages are associated with anti-inflammatory processes and promotion of repair, the excessive action of M2 macrophages may be detrimental as they can contribute to excessive pro-fibrotic function, leading to increased scarring [70]. Indeed, both mouse and human pathological specimens of the ischaemic heart show that cardiac fibrosis is associated with an increase in activated macrophages [71]; and a recent study also reveals that macrophages contribute collagen to scar formation [72]. Nevertheless, the neonatal heart is less fibrotic than the adult heart, the pro-fibrotic M2 macrophages might not be beneficial for neonatal heart regeneration. How Treg regulate the polarization of macrophages during development that may inherently possess different extent of reparative properties remains elusive, and further studies should further stratify the phenotype and function of different populations of macrophages in heart repair.

In addition to the immunomodulation of macrophages, Treg can also suppress the pro-inflammatory response of other activated cells such as effector CD4⁺ and CD8⁺ T cells. Intriguingly, a recent study shows a developmentally distinct role of CD4⁺ T cells in heart repair and regeneration [73]. CD4⁺ T cells inhibit heart regeneration in the juvenile mice but promote heart repair in the adult mice [73]. Unlike the CD4⁺ T cells, CD8⁺ T cells are found unresponsive to heart injury in the juvenile mice [73]. The pro-inflammatory cytokines of Th1 (e.g. TNF-α and IFN-γ) and Th17 (e.g. IL-17A) cells can directly inhibit the proliferation and promote the apoptosis of neonatal cardiomyocytes in vitro. Therefore, it is likely that Treg can also facilitate heart regeneration through inhibiting the pro-inflammatory activities of CD4⁺ Th1 and Th17 cells after myocardial injury.

Treg have also been shown to reduce the apoptosis of cardiomyocytes through a CD39 dependent mechanism. In vivo, the adoptive transfer of CD39 deficient (CD39^-/-) Treg fails to reduce the infarct size and cTnT levels after MI compared to the transfer of control Treg [74]. It has been previously reported that CD39 can catalyse the production of adenosine [29]. Co-culturing neonatal cardiomyocytes with adenosine alone reproduces the reduction of apoptosis seen in cardiomyocytes co-cultured with control Treg, whereas co-culture with the CD39 deficient Treg shows increased apoptosis [74]. Furthermore, the adoptive transfer of control Treg leads to increased activation of ERK1/2 and Akt, which belong to the RISK pathway; whereas the same activation is not observed after adoptive transfer of CD39-deficient Treg [74]. Therefore, Treg could protect cardiomyocytes from apoptosis through the CD39/adenosine/RISK pathway.

Furthermore, Treg can regulate cardiomyocyte regeneration by directly influencing their proliferation in the neonatal stage. The impaired regenerative capability of adult cardiomyocytes can be attributed not only to their binucleated property leading to cell cycle arrest but also to their developmentally different immune responses after injury. For instance, neonates have less effective Th1 and Th17 cell mediated responses that are poised to a Th2 immunity; and differentiation of Treg from naïve CD4⁺ T cells appears to be a default program [75]. Therefore, it is likely that Treg mediated cardiomyocyte regeneration is more apparent in the neonates. The underlying mechanism is suggested to be a paracrine effect, as the culture medium of Treg alone is sufficient to promote neonatal cardiomyocyte proliferation [64]. Further analysis of the genes upregulated in Treg after myocardial injury by single-cell RNA-sequencing and by studying the proliferative role of these factors in the neonatal cardiomyocyte cultures allowed the identification of potential candidates that can promote the proliferation of cardiomyocytes [64]. These factors include CCL24, GAS6, AREG, CST7, TNFSF11, IL33, FGL2, MATN2, and IGF2, and all of them were found to play a role in stimulating the proliferation of cardiomyocytes [63, 64]. These findings might have expanded the repertoire of the reparative capabilities of Treg through the communication with local parenchymal cells such as cardiomyocytes to promote tissue repair and regeneration.

The above evidence supports the notion that Treg participate in adult heart repair and neonatal heart regeneration after injury. How Treg respond to self-antigens after injury has been less studied. It has been reported that Treg of the myocardium can originate from several sources. Adoptive transfer of hCD2-expressing Treg by intraperitoneal injection into the Treg-deficient NOD/SCID mice shows that Treg can be found in the damaged myocardium during the first week after injury, suggesting that Treg can be recruited from the circulation [64]. Moreover, Treg are recruited through a CCR5-dependent mechanism to the myocardium after MI [76], and the recruited cardiac antigen-specific CD4⁺ T cells can be converted into Treg with the expression of FoxP3 and factors that promote healing [77]. In addition to differentiation from CD4⁺ T cells, proliferation of pre-existing Treg has also been reported. In one study, a small population of Treg is found to reside in a healthy heart of the adult mice, and the proliferation rate of Treg is elevated after injury resulting in an increased overall number of cardiac Treg [78]. Nevertheless, future work is required to determine what self-antigens can trigger the recruitment of reparative and regenerative functions of cardiac Treg; what signalling pathway can guide Treg expansion or differentiation from naïve Treg; and whether the reparative property of Treg is inherent to Treg, or exclusive to a particular subtype of Treg such as Foxp3⁺ Treg.

Clinical implications for treatment of cardiovascular diseases by Treg

Although there is a lack of clinical trial targeting the regenerative role of Treg, murine studies have already shown promising results of using Treg as a therapeutic strategy against cardiovascular diseases. For instance, adoptive transfer of Treg reduces cardiac fibrosis and promotes cardiac regeneration in the neonatal mice after cryoinfarction or apical resection [64]. Moreover, direct injection of Treg to the infarct zone of an adult heart after MI showed cell engraftment, leading to reduced infarct size and improved cardiac function for up to 3 months after injury [63]. Future research could examine the efficacy of Treg mediated tissue repair in humans because it is clinically feasible to expand or activate Treg. Currently, several clinical trials have been launched to examine the immunosuppressive function of Treg for potential treatment of autoimmune diseases through cytokine therapy, checkpoint blockade or adoptive transfer to enrich the Treg population.

For instance, IL-2 is essential for the growth and stability of Treg that express the IL-2 receptor (CD25). However, a challenge exists as IL-2 does not solely activate Treg but also other effector cells including CD4⁺ T cells, CD8⁺ T cells, or NK cells. To minimize non-specific activation, low-dose IL-2 has been demonstrated to selectively activate and expand Treg [79, 80]. Indeed, clinical trials utilizing low dose IL-2 have demonstrated safety and efficacy in the selective activation and expansion of Treg across 11 autoimmune diseases including rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus [81]. More recently, IL-2 mimics have been developed but research shows that these mimics contributed to expansion of immunosuppressive, antigen-specific Treg to a lesser extent compared to murine IL-2 [82]. More work is, therefore, needed to improve the efficiency and efficacy of IL-2 mimics in potential clinical use for Treg expansion. Moreover, targeting the PD-1/PD-L1 pathway can also expand Treg in the context of transplantation [83, 84]. Currently, there are already several anti-PD-1 or -PD-L1 antibodies used in the clinics for cancer immunotherapy so it could be in principle safe to test their effects in expanding Treg for tissue repair and regeneration. Furthermore, the CD28 superagonist has been re-investigated recently in humans. At a low dose, CD28 superagonist has been shown to preferentially expand and activate Treg in vitro, without the release of pro-inflammatory cytokine release by conventional T cells, which was thought to be the reason behind the fatal cytokine release syndrome experienced by patients in an earlier trial of the same drug [85]. Although CD28 superagonist is examined for its efficacy in small groups of patients in phase I trials for psoriasis, rheumatoid arthritis, and systemic lupus erythematosus (NCT01990157, NCT02796053, and NCT02711813, respectively), the results have not been officially published. Therefore, it remains unknown whether low dose CD28 superagonist is a safe and effective therapeutic agent to induce the immunosuppressive effects of Treg in humans.

Furthermore, adoptive transfer of autologous Treg has been examined as potential cell therapy for treatment of autoimmune diseases. For instances, ongoing clinical trials have been using polyclonal [86] or tissue-specific [87] Treg in patients with Type 1 diabetes. It has been reported that tissue-specific Treg, such as those targeting the pancreatic islets, are 50-100 times more effective in the prevention of disease progression of Type 1 diabetes [87]. Treg that are reactive to alloantigens have also shown to be more effective than polyclonal Treg in suppressing graft rejection [88], and alloantigen-reactive Treg are currently tested in clinical trial comparing the efficacy to conventional immunosuppressive drugs [87]. CAR Treg have also been developed to allow the development of specific Treg for therapy, and preclinical data have demonstrated that these cells are more effective than polyclonal Treg for reducing allograft rejection after transplanted in a humanised mouse model [89]. Our current understanding of the regenerative capability of Treg in promoting angiogenesis and cardiomyocyte regeneration is largely based on murine models. An obvious caveat of animal models is that murine Treg might not truly recapitulate the function of human Treg. These clinical trials using autologous Treg in cell therapy could ease the safety concern and provide some confidence for future investigation on the reparative role of human Treg. Taken together, these same approaches of Treg cell therapy might offer novel clinically relevant insights into the expansion and activation of Treg potentially facilitating tissue repair and regeneration in humans.

Future Perspectives

Treg take up a small proportion of the total immune cell population. It remains unclear how they exert such a large effect on the regulation of tissue repair and regeneration. One possible mechanism is mediated through the orchestration of other abundantly available immune cells. For instance, they can regulate the polarization of macrophages towards a pro-repair M2 phenotype for the regeneration of skeletal muscle [41]. Moreover, macrophages can directly contribute collagen to scar formation during zebrafish heart regeneration and adult mouse heart repair [72]. Whether Treg regulate macrophage mediated tissue repair and regeneration; and whether they regulate other immune cells in addition to macrophages for these processes require further investigation. In the context of transplantation, Treg are able to induce more Treg from naïve CD4⁺ T cells to acquire immunosuppressive regulatory functions through the process known as infectious tolerance [90]. Nevertheless, whether this infectious tolerance exists in the context of tissue repair and regeneration has not been elucidated.

Currently, most studies that evaluated the regenerative role of Treg focus on the conventional CD4⁺CD25⁺FoxP3⁺ Treg population. In fact, as our knowledge of Treg expands, Treg population is found to be heterogeneous. For instance, induction of T_H1 like-, T_H2 like-, and T_H17 like- Treg have been described under certain conditions, such as infection or a pathogenic process [91-94]. In the progression of chronic heart failure, Treg are found to be switched to the IFNγ expressing T_H1 like- phenotype that have reduced immunomodulatory abilities and increased anti-angiogenic and pro-fibrotic functions after the healing phase of MI [78]. Moreover, follicular regulatory T cells (T_FR), which are characterised by CD4⁺CXCR5^highPD-1^highFoxp3⁺, can also display suppressive mechanisms through GITR, IL-10, and ICOS, and function in the germinal centre to suppress the action of follicular helper T cells, and inhibit the selection for non-antigen-specific B cells [95]. In addition, CD8⁺ Treg are characterized as CD8⁺CD28^- and the majority of them also express FoxP3 [96]. CD8⁺CD28^- T cells were able to suppress CD4⁺ T cells by inducing apoptosis, inhibiting T cell activation and IFNγ expression through the release of IL-10, and reducing T cell proliferation via the release of IL-10 and TGF-β [97]. Importantly, some T cell subsets have regulatory functions but do not express FoxP3 including the CD8⁺CD122⁺ Treg [98], CD4⁺ Tr1 and Th3 Treg [99], CD4^-CD8^- αβ T cells [100], γδ T cells [100] and even the regulatory innate lymphoid cells [101]. Therefore, further work can also focus on the investigation of the potential regenerative role of the heterogeneous Treg population in addition to the conventional CD4⁺CD25⁺FoxP3⁺ cells in experiments related to tissue repair and regeneration.

While a large body of evidence uncovers the emerging role of Treg in promoting tissue repair and regeneration, some reports argue that Treg can also display detrimental function in disease states. For instance, patients with cardiovascular disease often have associated comorbidities such as hypertension and/or diabetes, and Treg has been reported defective in these comorbidities. Analysis of samples from patients with heart failure in one study and coronary artery disease in another study have both showed that the number of Treg of the diseased patients is reduced and Treg are less efficient in suppressing the proliferation and release of pro-inflammatory cytokines by CD4⁺CD25^- T cells compared to healthy controls [102, 103]. Consistent with these findings from human subjects, a murine model of chronic heart failure has also demonstrated that 90% of cardiac Treg express pro-inflammatory cytokines such as IFNγ and display reduced immunosuppressive ability and anti-angiogenic effect [78]. Their negative impact on adverse cardiac remodelling and impaired cardiac function of the failing heart can be abolished by specific ablation of Treg in Foxp3-DTR mice compared to that of the controls [78]. Furthermore, an epitope of the atheroprotective apolipoprotein B (ApoB) is found to be recognized by CD4⁺FOXP3⁺ Treg in healthy human subjects that is, however, recognized by Treg coexpressing other CD4 lineage markers in donors with subclinical cardiovascular disease [104]. These cells are absent in healthy donors but can also be found in patients with inflammatory disease [104]. Therefore, their role in promoting or protecting against atherosclerosis requires future investigations. Altogether, in certain pathological conditions, Treg also exhibit pro-inflammatory properties that could accelerate disease progression and may even operate against tissue repair and regeneration. Future studies characterising the plasticity of Treg function in the presence of cardiovascular comorbidities are needed to better understand their pathogenic role in disease development and progression.

Acknowledgements

This work was supported by Research Grants Council of Hong Kong (C4024-16W, C4026-17WF); National Natural Science Foundation of China (81922077); Croucher Foundation (Innovation Award and Start-up Allowance); University Grants Committee Research Matching Grant Scheme; Research Committee Funding, Direct Grant, Faculty Innovation Award, and Seed Fund from Lui Chi Woo Institute of Innovative Medicine.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107

2. Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol. 2013;9:25-34

3. Wang M, Jiang L, Monticone RE, Lakatta EG. Proinflammation: the key to arterial aging. Trends Endocrinol Metab. 2014;25:72-9

4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95

5. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90:464-70

6. Gieseck RL 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18:62-76

7. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523-32

8. Campbell C, Dikiy S, Bhattarai SK, Chinen T, Matheis F, Calafiore M. et al. Extrathymically generated regulatory T cells establish a niche for intestinal border-dwelling bacteria and affect physiologic metabolite balance. Immunity. 2018;48:1245-57

9. Lui KO, Boyd AS, Cobbold SP, Waldmann H, Fairchild PJ. A role for regulatory T cells in acceptance of ESC-derived tissues transplanted across an major histocompatibility complex barrier. Stem Cells. 2010;28:1905-14

10. Lui KO, Howie D, Ng SW, Liu SB, Chien KR, Waldmann H. Tolerance induction to human stem cell transplants with extension to their differentiated progeny. Nat Commun. 2014;5:5629

11. Dhamne C, Chung Y, Alousi AM, Cooper LJ, Tran DQ. Peripheral and thymic foxp3(+) regulatory T cells in search of origin, distinction, and function. Front Immunol. 2013;4:253

12. Kanamori M, Nakatsukasa H, Okada M, Lu QJ, Yoshimura A. Induced regulatory T cells: Their development, stability, and applications. Trends Immunol. 2016;37:803-11

13. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R. et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4:1206-12

14. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB. et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002;297:1867-70

15. Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L. et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180:5916-26

16. Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol. 2008;180:6649-55

17. Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A. 2004;101:10398-403

18. Kearley J, Barker JE, Robinson DS, Lloyd CM. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4(+) CD25(+) regulatory T cells is interleukin 10 dependent. J Exp Med. 2005;202:1539-47

19. D'Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF. et al. CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest. 2009;119:2898-913

20. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM. et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566-9

21. Kinsey GR, Sharma R, Huang L, Li L, Vergis AL, Ye H. et al. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol. 2009;20:1744-53

22. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A. 2007;104:19446-51

23. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 2007;26:579-91

24. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel-disease in scid mice reconstituted with Cd45rb(Hi) Cd4(+) T-Cells. Immunity. 1994;1:553-62

25. Chinen T, Kannan AK, Levine AG, Fan XY, Klein U, Zheng Y. et al. An essential role for the IL-2 receptor in T-reg cell function. Nat Immunol. 2016;17:1322-33

26. Sitrin J, Ring A, Garcia KC, Benoist C, Mathis D. Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med. 2013;210:1153-65

27. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257-65

28. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5 '-adenosine monophosphate to adenosine. J Immunol. 2006;177:6780-6

29. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R. et al. Expression of ectonucleotidase CD39 by Foxp3(+) Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225-32

30. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21:589-601

31. Cao XF, Cai SF, Fehniger TA, Song JL, Collins LI, Piwnica-Worms DR. et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27:635-46

32. Ren X, Ye F, Jiang Z, Chu Y, Xiong S, Wang Y. Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells. Cell Death Differ. 2007;14:2076-84

33. Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid tissues. Nat Immunol. 2013;14:1007-13

34. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15:930-9

35. Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE. et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue T-reg cells. Nature. 2012;486:549-53

36. Sather BD, Treuting P, Perdue N, Miazgowicz M, Fontenot JD, Rudensky AY. et al. Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease. J Exp Med. 2007;204:1335-47

37. Dudda JC, Perdue N, Bachtanian E, Campbell DJ. Foxp3(+) regulatory T cells maintain immune homeostasis in the skin. J Exp Med. 2008;205:1559-65

38. Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A. et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Brit J Dermatol. 2010;162:1056-63

39. Antiga E, Kretz CC, Klembt R, Massi D, Ruland V, Stumpf C. et al. Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmun. 2010;35:342-50

40. Richards DM, Delacher M, Goldfarb Y, Kagebein D, Hofer AC, Abramson J. et al. Treg cell differentiation: From thymus to peripheral tissue. Prog Mol Biol Transl. 2015;136:175-205

41. Villalta SA, Rosenthal W, Martinez L, Kaur A, Sparwasser T, Tidball JG. et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med. 2014;6:258ra142

42. Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A. et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med. 2007;204:1057-69

43. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y. et al. A special population of regulatory T cells potentiates muscle repair. Cell. 2013;155:1282-95

44. Tabebordbar M, Wang ET, Wagers AJ. Skeletal muscle degenerative diseases and strategies for therapeutic muscle repair. Annu Rev Patho. 2013;8:441-75

45. Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, Yuan SP. et al. A distinct function of regulatory T cells in tissue protection. Cell. 2015;162:1078-89

46. Dial CF, Tune MK, Doerschuk CM, Mock JR. Foxp3(+) regulatory T cell expression of keratinocyte growth factor enhances lung epithelial proliferation. Am J Respir Cell Mol Biol. 2017;57:162-73

47. Biton M, Haber AL, Rogel N, Burgin G, Beyaz S, Schnell A. et al. T helper cell cytokines modulate intestinal stem cell renewal and differentiation. Cell. 2018;175:1307-20

48. Rodriguez RS, Pauli ML, Neuhaus IM, Yu SS, Arron ST, Harris HW. et al. Memory regulatory T cells reside in human skin. J Clin Invest. 2014;124:1027-36

49. Ali N, Zirak B, Rodriguez RS, Pauli ML, Truong HA, Lai KV. et al. Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell. 2017;169:1119-29

50. Mathur AN, Zirak B, Boothby IC, Tan M, Cohen JN, Mauro TM. et al. Treg-cell control of a CXCL5-IL-17 inflammatory axis promotes hair-follicle-stem-cell differentiation during skin-barrier Repair. Immunity. 2019;50:655-67

51. Dombrowski Y, O'Hagan T, Dittmer M, Penalva R, Mayoral SR, Bankhead P. et al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat Neurosci. 2017;20:674-80

52. Pierini A, Nishikii H, Baker J, Kimura T, Kwon HS, Pan YQ. et al. Foxp3(+) regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. Nat Commun. 2017;8:15068

53. Facciabene A, Peng XH, Hagemann IS, Balint K, Barchetti A, Wang LP. et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T-reg cells. Nature. 2011;475:226-30

54. Leung OM, Li JT, Li XS, Chan VW, Yang KY, Ku MC. et al. Regulatory T cells promote apelin-mediated sprouting angiogenesis in type 2 diabetes. Cell Rep. 2018;24:1610-26

55. Sharir R, Semo J, Shaish A, Landa-Rouben N, Entin-Meer M, Keren G. et al. Regulatory T cells influence blood flow recovery in experimental hindlimb ischaemia in an IL-10-dependent manner. Cardiovasc Res. 2014;103:585-96

56. Liang C, Yang KY, Chan VW, Li XS, Fung THW, Wu YL. et al. CD8(+) T-cell plasticity regulates vascular regeneration in type-2 diabetes. Theranostics. 2020;10:4217-32

57. Huang MT, Dai YS, Chou YB, Juan YH, Wang CC, Chiang BL. Regulatory T cells negatively regulate neovasculature of airway remodeling via DLL4-Notch signaling. J Immunol. 2009;183:4745-54

58. Hui SP, Sheng DZ, Sugimoto K, Gonzalez-Rajal A, Nakagawa S, Hesselson D. et al. Zebrafish regulatory T cells mediate organ-specific regenerative programs. Dev Cell. 2017;43:659-72

59. Lazar E, Sadek HA, Bergmann O. Cardiomyocyte renewal in the human heart: insights from the fall-out. Eur Heart J. 2017;38:2333-42

60. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN. et al. Transient regenerative potential of the neonatal mouse heart. Science. 2011;331:1078-80

61. Lam NT, Sadek HA. Neonatal heart regeneration: Comprehensive literature review. Circulation. 2018;138:412-23

62. Weirather J, Hofmann UD, Beyersdorf N, Ramos GC, Vogel B, Frey A. et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res. 2014;115:55-67

63. Zacchigna S, Martinelli V, Moimas S, Colliva A, Anzini M, Nordio A. et al. Paracrine effect of regulatory T cells promotes cardiomyocyte proliferation during pregnancy and after myocardial infarction. Nat Commun. 2018;9:2432

64. Li J, Yang KY, Tam RCY, Chan VW, Lan HY, Hori S. et al. Regulatory T-cells regulate neonatal heart regeneration by potentiating cardiomyocyte proliferation in a paracrine manner. Theranostics. 2019;9:4324-41

65. Tang TT, Yuan J, Zhu ZF, Zhang WC, Xiao H, Xia N. et al. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res Cardiol. 2012;107:232

66. Dick SA, Macklin JA, Nejat S, Momen A, Clemente-Casares X, Althagafi MG. et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. Nat Immunol. 2019;20:29-39

67. Fujiu K, Wang J, Nagai R. Cardioprotective function of cardiac macrophages. Cardiovasc Res. 2014;102:232-9

68. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B. et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity. 2014;40:91-104

69. Lavine KJ, Epelman S, Uchida K, Weber KJ, Nichols CG, Schilling JD. et al. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. P Natl Acad Sci U S A. 2014;111:16029-34

70. Braga TT, Agudelo JSH, Camara NOS. Macrophages during the fibrotic process: M2 as friend and foe. Front Immunol. 2015;6:602

71. Carlson S, Helterline D, Asbe L, Dupras S, Minami E, Farris S. et al. Cardiac macrophages adopt profibrotic/M2 phenotype in infarcted hearts: Role of urokinase plasminogen activator. J Mol Cell Cardiol. 2017;108:42-9

72. Simoes FC, Cahill TJ, Kenyon A, Gavriouchkina D, Vieira JM, Sun X. et al. Macrophages directly contribute collagen to scar formation during zebrafish heart regeneration and mouse heart repair. Nat Commun. 2020;11:600

73. Li J, Liang C, Yang KY, Huang X, Han MY, Li XS. et al. Specific ablation of CD4+ T-cells promotes neonatal heart regeneration in mice. Theranostics. 2020;10:8018-8035

74. Xia N, Jiao J, Tang TT, Lv BJ, Lu YZ, Wang KJ. et al. Activated regulatory T-cells attenuate myocardial ischaemia/reperfusion injury through a CD39-dependent mechanism. Clin Sci. 2015;128:679-93

75. Debock I, Flamand V. Unbalanced neonatal CD4(+) T-cell immunity. Front Immunol. 2014;5:393

76. Dobaczewski M, Xia Y, Bujak M, Gonzalez-Quesada C, Frangogiannis NG. CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. Am J Pathol. 2010;176:2177-87

77. Rieckmann M, Delgobo M, Gaal C, Buchner L, Steinau P, Reshef D. et al. Myocardial infarction triggers cardioprotective antigen-specific T helper cell responses. J Clin Invest. 2019;129:4922-36

78. Bansal SS, Ismahil MA, Goel M, Zhou GH, Rokosh G, Hamid T. et al. Dysfunctional and proinflammatory regulatory T-lymphocytes are essential for adverse cardiac remodeling in ischemic cardiomyopathy. Circulation. 2019;139:206-21

79. Hirakawa M, Matos T, Liu HY, Koreth J, Kim HT, Paul NE. et al. Low-dose IL-2 selectively activates subsets of CD4(+) Tregs and NK cells. JCI Insight. 2016;1:e89278

80. Yu AX, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A. et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes. 2015;64:2172-83

81. Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78:209-17

82. Silva DA, Yu S, Ulge UY, Spangler JB, Jude KM, Labao-Almeida C. et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019;565:186-91

83. Leung CS, Yang KY, Li XS, Chan VW, Ku MC, Waldmann H. et al. Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells. Genome Med. 2018;10:71

84. Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y. et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. P Natl Acad Sci U S A. 2019;116:9999-10008

85. Tabares P, Berr S, Romer PS, Chuvpilo S, Matskevich AA, Tyrsin D. et al. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol. 2014;44:1225-36

86. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK. et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7:315ra189

87. Bluestone JA, Tang QZ. T-reg cells-the next frontier of cell therapy: Will regulatory T cells be a frontline therapy for autoimmunity and other diseases? Science. 2018;362:154-5

88. Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA. et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant. 2013;13:3010-20

89. Boardman DA, Philippeos C, Fruhwirth GO, Ibrahim MAA, Hannen RF, Cooper D. et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am J Transplant. 2017;17:931-43

90. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: Human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med. 2002;196:255-60

91. Oldenhove G, Bouladoux N, Wohlfert EA, Hall JA, Chou D, Dos Santos L. et al. Decrease of Foxp3(+) Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity. 2009;31:772-86

92. Feng T, Cao AT, Weaver CT, Elson CO, Cong YZ. Interleukin-12 converts Foxp3(+) regulatory T cells to interferon-gamma-producing Foxp3(+) T cells that inhibit colitis. Gastroenterology. 2011;140:2031-43

93. Rivas MN, Burton OT, Wise P, Charbonnier LM, Georgiev P, Oettgen HC. et al. Regulatory T cell reprogramming toward a Th2-cell-like lineage impairs oral tolerance and promotes food allergy. Immunity. 2015;42:512-23

94. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T. et al. Pathogenic conversion of Foxp3(+) T cells into T(H)17 cells in autoimmune arthritis. Nat Med. 2014;20:62-8

95. Linterman MA, Pierson W, Lee SK, Kallies A, Kawamoto S, Rayner TF. et al. Foxp3(+) follicular regulatory T cells control the germinal center response. Nat Med. 2011;17:975-82

96. Chen XY, Liu QL, Xiang AP. CD8+CD28-T cells: not only age-related cells but a subset of regulatory T cells. Cell Mol Immunol. 2018;15:734-6

97. Liu QL, Zheng HQ, Chen XY, Peng YW, Huang WJ, Li XB. et al. Human mesenchymal stromal cells enhance the immunomodulatory function of CD8(+) CD28(-) regulatory T cells. Cell Mol Immunol. 2015;12:708-18

98. Liu JF, Chen DC, Nie GD, Dai ZH. CD8(+)CD122(+) T-cells: A newly emerging regulator with central memory cell phenotypes. Front Immunol. 2015;6:494

99. Jonuleit H, Schmitt E. The regulatory T cell family: Distinct subsets and their interrelations. J Immunol. 2003;171:6323-7

100. D'Alessio FR, Kurzhagen JT, Rabb H. Reparative T lymphocytes in organ injury. J Clin Invest. 2019;129:2608-18

101. Wang S, Xia PY, Chen Y, Qu Y, Xiong Z, Ye BQ. et al. Regulatory innate lymphoid cells control innate intestinal inflammation. Cell. 2017;171:201-16

102. Tang TT, Ding YJ, Liao YH, Yu X, Xiao H, Xie JJ. et al. Defective circulating CD4(+)CD25(+)Foxp3(+)CD127(low) regulatory T-cells in patients with chronic heart failure. Cell Physiol Biochem. 2010;25:451-8

103. Hasib L, Lundberg AK, Zachrisson H, Ernerudh J, Jonasson L. Functional and homeostatic defects of regulatory T cells in patients with coronary artery disease. J Intern Med. 2016;279:63-77

104. Kimura T, Kobiyama K, Winkels H, Tse K, Miller J, Vassallo M. et al. Regulatory CD4(+) T cells recognize major histocompatibility complex class II molecule-restricted peptide epitopes of apolipoprotein B. Circulation. 2018;138:1130-43

Author contact

Corresponding author: E-mail: kathyoluiedu.hk (K.O.L.).

Received 2020-4-17
Accepted 2020-6-16
Published 2020-7-11

Citation styles

©2024 Ivyspring International Publisher. Terms of use